Fairvalue-Calculator Fairvalue-Calculator
EN DE

Senhwa Biosciences, Inc (6492) Fair Value & Analysis

Healthcare · TW · Market cap 4.0B TWD

Price42.60 TWD
Fair Value25.54 TWD
Upside-40.0%
Quality95/100
Evidence: Low Range 19.15 TWD – 31.92 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Senhwa Biosciences, Inc (6492) currently trades at 42.60 TWD, while our model-based Fair Value estimate is 25.54 TWD — implying the stock looks roughly 40.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Senhwa Biosciences, Inc (6492) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 25.54 TWD versus a price of 42.60 TWD — about −40% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6492?
Our 21-model fair value for Senhwa Biosciences, Inc is 25.54 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 42.60 TWD.
What is the quality score of 6492?
Senhwa Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.